Safety of drugs used in assisted reproduction techniques

Drug Safety

Volumn 28, Issue 6, 2005, Pages 513-528

  Al Shawaf, Talha ^a   Zosmer, Ariel ^a   Dirnfeld, Martha ^a   Grudzinskas, Gedis ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLOMIFENE; ESTRADIOL; FERTILITY PROMOTING AGENT; GONADORELIN AGONIST; HUMAN MENOPAUSAL GONADOTROPIN; PROGESTERONE;

ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; AZOOSPERMIA; BREAST CARCINOMA; CANCER RISK; CEREBROVASCULAR ACCIDENT; CHILDHOOD CANCER; CONGENITAL MALFORMATION; CYST; DISEASE COURSE; DISEASE SEVERITY; DRUG SAFETY; DYSPNEA; HEADACHE; HIGH RISK PATIENT; HOT FLUSH; HUMAN; INTRACYTOPLASMIC SPERM INJECTION; KIDNEY FAILURE; LUTEAL INSUFFICIENCY; LUTEAL PHASE; LUTEOLYSIS; MALE INFERTILITY; NAUSEA; OOCYTE; OVARY CARCINOMA; OVARY FOLLICLE; OVARY HYPERSTIMULATION; OVULATION; PAIN; PREGNANCY; PRIORITY JOURNAL; REDUCTION; REPRODUCTION; RESPIRATORY TRACT DISEASE; REVIEW; RISK FACTOR; SKIN MANIFESTATION; THROMBOEMBOLISM; WITHDRAWAL SYNDROME;

GONADOTROPINS; HUMANS; INFERTILITY; REPRODUCTIVE TECHNIQUES, ASSISTED;

EID: 22344454947     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200528060-00004     Document Type: Review

References (152)

1. Steptoe PC, Edwards RG. Birth after the reimplantation of a human embryo. Lancet 1978; II (8085): 366
2. Fishel SB, Edwards RG, Purdy JM, et al. Implantation, abortion, and birth after in vitro fertilization using the natural menstrual cycle or follicular stimulation with clomiphene citrate and human menopausal gonadotropin. J In Vitro Fert Embryo Transf 1985; 2 (3): 123-31
3. In vitro fertilization/embryo transfer in the United States: 1985 and 1986 results from the National IVF/ET Registry. Medical Research International. The American Fertility Society Special Interest Group. Fertil Steril 1988; 49 (2): 212-5
4. Laufer N, DeCherney AH, Haseltine FP, et al. The use of highdose human menopausal gonadotropin in an in vitro fertilization program. Fertil Steril 1983; 40 (6): 734-41
5. Fraser HM, Baird DT. Clinical applications of LHRH analogues. Baillieres Clin Endocrinol Metab. 1987; 1 (1): 43-70
6. Tarlatzis BC, Bili H. Safety of GnRH agonists and antagonists. Expert Opin Drug Saf 2004; 3 (1): 39-46
7. Macnamee MC, Howles CM, Edwards RG. Pregnancies after IVF when high tonic LH is reduced by long-term treatment with GnRH agonists. Hum Reprod 1987; 2 (7): 569-71
8. Frydman R, Parneix I, Belaisch-Allart J, et al. LHRH agonists in IVF: different methods of utilization and comparison with previous ovulation stimulation treatments. Hum Reprod 1988; 3 (4): 559-61
9. Olivennes F, Cunha-Filho JS, Fanchin R, et al. The use of GnRH antagonists in ovarian stimulation. Hum Reprod Update 2002; 8 (3): 279-90
10. Penzias AS. Luteal phase support. Fertil Steril 2002; 77 (2): 318-23
11. Kurinczuk JJ. Safety issues in assisted reproduction technology: from theory to reality - just what are the data telling us about ICSI offspring health and future fertility and should we be concerned? Hum Reprod 2003; 18 (5): 925-31
12. Henzel RM. Gonadotrophin-releasing hormone and its analogues: from laboratory to bedside. Clin Obstet Gynaecol 1993; 36: 617-35
13. Sealfon SC, Weinstein H, Millar RP. Molecular mechanism of ligand interaction with the gonadotrophin-releasing hormone receptor. Endocr Rev 1997; 18: 180-205
14. Engman L, Maconochie N, Bekir J, et al. Progesterone therapy during pituitary desensitisation with gonadotrophin-releasing hormone agonist prevent functional ovarian cyst formation: a prospective randomised study. Am J Obstet Gynecol 1999; 181: 576-82
15. Ferraretti AP, Magli C, Feliciani E, et al. Relationship of timing of agonist administration in the cycle phase to the ovarian response to the gonadotrophin in the long down-regulation protocols for assisted reproduction technologies. Fertil Steril 1996; 65: 114-21
16. Jenkins JM, Anthony FW, Lee A, et al. Persistance elevation of serum oestradiol levels by functional ovarian cysts despite effective pituitary desensitisation with GnRH agonist. Clin Endocrinol 1994; 40: 357-9
17. Tarlatzis BC, Bili H, Bontis J, et al. Follicle cyst formation after administration of different GnRH analogues for assisted reproduction. Hum Reprod 1994; 9: 1983-6
18. Damario MA, Moy F, Moomjy M, et al. Delay of gonadotrophin stimulation in patients receiving gonadotrophin-releasing hormone agonist (GnRH-a) therapy permits increased clinic efficiency and may enhance in vitro fertilization (IVF) pregnancy rates. Fertil Steril 1997; 68: 1004-10
19. Engel G, Huston M, Oshima S, et al. Pituitary apoplexy after leuprolide injection for ovarian donation. J Adolesc Health, 2003; 32: 89-93
20. El Nemer A, Bhide M, Khalifa Y, et al. Clinical evaluation of three different gonadotrophin-releasing hormone analogues in an IVF programme: a prospective study. Eur J Obstet Gynaecol Reprod Biol 2002; 103: 140-5
21. Gonen Y, Dirnfeld M, Abramovici H. Outcome of pregnancies inadvertently exposed to gonadotrophin-releasing hormone analogues (GnRHa) in early gestation. Assist Reprod Genet 1993; 10: 437-9
22. Plattea UP, Gabbe M, Famelos M, et al. Should we still advise infertile couples to use (barrier) contraception before IVF down-regulation? Fertil Steril 2000; 74: 655-9
23. Cahill D J, Fountin SA, Fox R, et al. Outcome of inadvertent administration of a gonadotrophin-releasing hormone agonist (buserelin) in early pregnancy. Hum Reprod 1994; 9: 1243-6
24. Smitz J, Erard P, Camms M, et al. Pituitary gonadotrophin secretion capacity during luteal phase in super ovulation using GnRH agonists and HMG in a desensitisation or flare up protocol. Hum Reprod 1992; 7: 1225-9
25. Pritts EA, Atwood AK. Luteal phase support in infertility treatment: a meta-analysis of the randomized trials. Hum Reprod 2002; 17 (9): 2287-99
26. Zeevi D, Younis JS, Laufer N. Ovulation induction - new approaches. Assist Reprod Rev 1991; 1: 2-8
27. Rizk B, Smitz J. Ovarian hyperstimulation syndrome after super ovulation using GnRH agonists for IVF and related procedures. Hum Reprod 1992; 7: 320-7
28. Reissman T, Felberbaum RG, Diedrich K, et al. Development and applications of luteinizing hormone-releasing hormone antagonists in the treatment of infertility: an overview. Hum Reprod 1995; 10: 1974-81
29. Duijkers IJ, Klipping C, Willemsen WN, et al. Single and multiple dose pharmacokinetics and pharmokodynamics of the gonadotrophin-releasing hormone antagonists cetrorelix in healthy female volunteers. Hum Reprod 1998; 13: 2392-8
30. Mannaerts B, Oberye J, Peters M, et al. Introduction to the GnRH antagonist ganirelix (Orgalutran). Gynecol Endocrinol 1999; 13 (suppl): 12
31. Felderbaum RE, Albano C, Ludwig M, et al. Ovarian stimulation for assisted reproduction with HMG and concomitant midcycle administration of the GnRH antagonist Cetrorelix according to the multiple dose protocol; a prospective uncontrolled phase III study on behalf of the European Cetrorelix Study Group. Hum Reprod 2000; 15: 1015-20
32. Al-Inany H, Aboulghar M. GnRH antagonist in assisted reproduction: a Cochrane review. Hum Reprod. 2002; 17 (4): 874-85
33. Janssens RM, Brus L, Cahill DJ, et al. Direct ovarian effects and safety aspects of GnRH agonists and antagonists. Hum Reprod Update. 2000; 6 (5): 505-18
34. Cook AS, Webster BW, Terranova PF, et al. Variation in the biologic and biochemical characteristics of human menopausal gonadotrophin. Fertil Steril 1988; 49: 704-12
35. Le Cotonnec JY, Porchet HC, Beltrami VC, et al. Comparative pharmacokinetics of two urinary follicle stimulating hormone preparations in healthy female and male volunteers. Hum Reprod 1993; 8: 1604-11
36. Nichols J, Knocheuhauer E, Fein SH, et al. Subcutaneously administered Repronex in oligoovulatory female patients undergoing ovulation induction is as effective and well tolerated as intramuscular human menopausal gonadotrophin treatment. Fertil Steril 2001; 76: 58-66
37. Li TC, Hindle JE. Adverse local reaction to intramuscular injections of urinary gonadotrophin. Hum Reprod 1993; 8: 1835-6
38. Engmann L, Shaker A, White E, et al. A prospective randomised study to assess the clinical efficacy of gonadotrophins administered subcutaneously and intramuscularly. Hum Reprod 1998; 13: 836-40
39. Kelly E. Recombinant human follicle-stimulating hormone versus urinary-derived human menopausal gonadotropin for controlled ovarian stimulation: the science and art of assisted reproductive technologies. Fertil Steril 2003; 80 (5): 1105-7
40. Balen A. Is there a risk of prion disease after the administration of urinary-derived gonadotrophins? Hum Reprod 2002; 17 (7): 1676-80
41. Pritts EA, Atwood AK. Luteal support in infertility treatment: a metanalysis of the randomised trials. Hum Reprod 2002; 17: 2287-99
42. Schindler AE, Campagnoli C, Druckmann R, et al. Classification and pharmacology of progestins. Maturitas 2003; 46 Suppl. 1: S7-S16
43. Jones HW Jr, Wilkins L. The genital anomaly associated with prenatal exposure to progestogens. Fertil Steril 1960; 11: 148-525
44. Briggs MH. Hypospadias, androgen biosynthesis, and synthetic progestogens during pregnancy. Int J Fertil. 1982; 27 (2): 70-2
45. Raman-Wilms L, Tseng AL, Wighardt S, et al. Fetal genital effects of first-trimester sex hormone exposure: a meta-analysis. Obstet Gynecol 1995; 8 (1): 141-9
46. Tavaniotou A, Smitz J, Bourgain C, et al. Comparison between different routes of progesterone administration as luteal phase support in infertility treatments. Hum Reprod Update 2000; 6: 139-48
47. Daya S, Gunby S. Luteal support in assisted reproduction cycles. Chocrane Database Syst Rev 2004; 3: CD004830
48. McClure N, Leya J, Radwawka E, et al. Luteal phase support and severe ovarian hyperstimulation syndrome. Hum Reprod 1992; 7: 758-64
49. Ovarian cancer. Gynecological neoplasms. Section 18, chapter 241. In: Beers MH, Berkow R, editors. The Merk Manual, 17th edition. New Jersey: Rathway: Merk, Sharp and Dohme, 2003
50. Atlas M, Menczer J. Massive hyperstimulation and borderline carcinoma of the ovary: a possible association. Acta Obstet Gynecol Scand 1982; 61: 261-3
51. Bamford PN, Steele SJ. Uterine and ovarian carcinoma in a patient receiving Gonadotrophin therapy: case report. Br J Obstet Gynaecol 1982; 89: 962-4
52. Ben-Hur H, Dgani R, Lancet M, et al. Ovarian carcinoma masquerading as ovarian hyperstimulation syndrome. Acta Obstet Gynecol Scand 1986; 65: 813-4
53. Dietl J. Ovulation and ovarian cancer [letter]. Lancet 1991; 338: 445
54. Kulkarni R, McGarry JM. Follicular stimulation and ovarian cancer [letter]. BMJ 1989; 299: 740
55. Ron E, Lunenfeld B, Menczer J, et al. Cancer incidence in a cohort of infertile women. Am J Epidemiol 1987; 125: 780-90
56. Fishel S, Jackson P. Follicular stimulation for high-tech pregnancies: are we playing it safe? BMJ 1989; 299: 309-31
57. Spirtas R, Kaufman SC, Alexander NJ. Fertility drugs and ovarian cancer: red alert or red herring? Fertil Steril 1993; 59: 291-3
58. Willemsen W, Kruitwagen R, Bastiaans B, et al. Ovarian stimulation and granulosa-cell tumour. Lancet 1993; 341: 986-8
59. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancer in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992; 136: 1184-203
60. Harris R, Whittemore AS, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. III. Epithelial tumours of low malignant potential in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992; 136: 1204-11
61. Horn-Ross PL, Whittemore AS, Harris R, et al. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. VI. Non-epithelial cancers among adults. Collaborative Ovarian Cancer Group. Epidemiology 1992; 3: 490-5
62. Brinton LA, Melton LJ III, Malkasian GD Jr, et al. Cancer risk after evaluation for infertility. Am J Epidemiol 1989; 129: 712-22
63. Whittemore AS. The risk of ovarian cancer after treatment for infertility. N Eng J Med 1994; 331: 805-6
64. Rossing MA, Daling JR, Weiss NS, et al. Ovarian tumors in a cohort of infertile women. N Eng J Med 1994; 331: 771-6
65. Carter ME, Joyce DN. Ovarian carcinoma in a patient hyperstimulated by gonadotropin therapy for in-vitro fertilisation: a case report. J In Vitro Fert Embryo Transfer 1987; 4: 126-8
66. Nijman HW, Burger CW, Baak JPA, et al. Borderline malignancy of the ovary and controlled hyperstimulation. A report of 2 cases. Eur J Cancer 1992; 28: 1971-3
67. Grimbizis G, Tarlatzis BC, Bontis J, et al. Two cases of ovarian tumours in women who had undergone multiple ovarian stimulation attempts. Hum Reprod 1995; 10: 520-3
68. Venn A, Watson L, Bruisma F, et al. Risk of cancer after use of fertility drugs with in-vitro fertilisation. Lancet 1999; 354: 1586-90
69. Venn A, Watson L, Lumley J, et al. Breast and ovarian cancer incidence after infertility and in-vitro fertilisation. Lancet 1995; 346: 995-1000
70. Unkila-Kallio L, Leminen A, Tiitinen A, et al. Nationwide data on falling incidence of ovarian granulosa cell tumours concomitant with increasing use of ovulation inducers. Hum Reprod 1998; 13: 2828-30
71. Dor J, Lerner-Geva L, Rabinovici J, et al. Cancer incidence in a cohort of infertile women who underwent in-vitro fertilisation. Fertil Steril 2001; 77: 324-7
72. Brinton LA, Lamb EJ, Moghissi KS, et al. Ovarian cancer risk after the use of ovulation-stimulating drugs. Obstet Gynecol 2004; 103: 1194-203
73. Kashyap S, Davis OK. Ovarian cancer and fertility medications: a critical appraisal. Semin Reprod Med 2003; 21 (1): 65-71
74. Kashyap S, Moher D, Fung M, et al. Assisted Reproductive Technology and the incidence of ovarian cancer: a meta-analysis. Obset Gynecol 2004; 103: 785-94
75. Breast cancer. Breast disorders. Section 18, chapter 242. In: Beers MH, Berkow R, editors. The Merk Manual, 17th edition. New Jersey: Rathway: Merk, Sharp and Dohme, 2003
76. Potashnik G, Lerner-Geva L, Genkin L, et al. Fertility drugs and the risk of breast and ovarian cancers: results of a long-term follow-up study. Fertil Steril 1999; 71 (5): 853-9
77. Siegelmann-Danieli N, Tamir A, Zohar H, et al. Breast cancer in women with recent exposure to fertility medications is associated with poor prognostic features. Ann Surg Oncol 2003; 10 (9): 1031-8
78. Brinton LA, Melton LJ, Malkasian GD, et al. Cancer risk after evaluation for infertility. Am J Epidemiol 1989; 129: 712-22
79. Rossing MA, Daling JR, Weiss MS, et al. Risk of breast cancer in a cohort of infertile women. Gynecol Oncol 1996; 60: 3-7
80. Lee SH, Akuete K, Fulton J, et al. An increased risk of breast cancer after delayed first parity. Am J Surg 2003; 186 (4): 409-12
81. Ricci E, Parazzini F, Negri E, et al. Fertility drugs and the risk of breast cancer. Hum Reprod 2001; 16 (1): 196
82. Fertility drugs may not increase risk of invasive ovarian cancer. Mayo Clin Womens Healthsource 2002; 6 (5): 3
83. Burkman RT, Tang MT, Malone KE, et al. Infertility drugs and the risk of breast cancer: findings from the National Institute of Child Health and Human Development Women's Contraceptive and Reproductive Experiences Study. Fertil Steril 2003; 79 (4): 844-51
84. Schieve LA, Rasmussen SA, Buck GM, et al. Are children born after Assisted Reproductive Technology at increased risk for adverse health outcome? Obstet Gynecol 2004; 103: 1154-63
85. Venn A, Healy AV, McLachlan R. Cancer risks associated with the diagnosis of infertility. Best Pract Res Clin Obstet Gynaecol 2003; 17: 343-67
86. Brinton LA, Kruger KS, Thomsen BL, et al. Childhood tumor risk after treatment with ovulation-stimulation drugs. Fertil Steril 2004; 81: 1083-91
87. Practice Committee of the American Society for Reproductive Medicine, American Society for Reproductive Medicine, Birmingham, Alabama, USA. Ovarian hyperstimulation syndrome. Fertil Steril 2003; 80 (5): 1309-14
88. Mathur R, Jenkins J. Ovarian hyperstimulation syndrome: an endocrinopathy? Curr Opin Obstet Gynecol 2001; 13 (3): 329-33
89. Kaiser UB. The pathogenesis of the ovarian hyperstimulation syndrome. N Engl J Med 2003; 349 (8): 729-32
90. Enskog A, Henriksson M, Unander M, et al. Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril 1999; 71: 808-14
91. Navot D, Bergh PA, Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril 1992; 58 (2): 249-61
92. Golan A, Ron-el R, Sofer Y, et al. Ovarian hyperstimulation syndrome: an update review. Obstet Gynecol Surv 1989; 44 (6): 430-40
93. Blankstein J, Shalev J, Saadon T, et al. Ovarian hyperstimulation syndrome: prediction by number and size of preovulatory ovarian follicles. Fertil Steril 1987; 47: 597-602
94. Evbuomwan IO, Davison JM, Murdoch AP. Coexistent hemoconcentration and hypoosmolarity during superovulation and in severe ovarian hyperstimulation syndrome: a volume homeostatic paradox. Fertil Steril 2000; 74 (1): 67-72
95. Mathur RS, Akande AV, Keay SD, et al. Distinction between early and late ovarian hyperstimulation syndrome. Fertil Steril 2000; 73: 901-7
96. Dahl Lyons CA, Wheeler CA, Fishman GN, et al. Early and late presentation of the ovarian hyperstimulation syndrome: two distinct entities with different risk factors. Hum Reprod 1994; 9: 792-9
97. Delvigne A, Rozenberg S. Preventive attitude of physicians to avoid OHSS in IVF patients. Hum Reprod 2001; 16: 2491-5
98. McClure N, Healy DL, Roger PAW, et al. Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome. Lancet 1994; 344: 235-6
99. Benadiva CA, Davis O, Kligman I, et al. Withholding gonadotropin administration is an effective alternative for the prevention of ovarian hyperstimulation syndrome. Fertil Steril 1997; 67: 724-7
100. Al-Shawaf T, Zosmer A, Hussain S, et al. Prevention of ovarian hyperstimulation syndrome in IVF with or without ICSI and embryo transfer: a modified 'coasting' strategy based on ultrasound for identification of high-risk patients. Hum Reprod 2001; 16: 24-30
101. Waldenström U, Kahn J, Marsk L, Nilsson S. High pregnancy rates and successful prevention of severe ovarian hyperstimulation syndrome by 'prolonged coasting' of very hyperstimulated patients: a multicentre study. Hum Reprod 1999; 14: 294-7
102. Sher G, Zouves C, Feinman M, et al. 'Prolonged coasting': an effective method for preventing severe ovarian hyperstimulation syndrome in patients undergoing in-vitro fertilization. Hum Reprod 1995; 10: 3107-9
103. Fluker MR, Hooper WM, Yuzpe AA. Withholding gonadotrophin ('coasting') to minimize the risk of ovarian hyperstimulation during super ovulation and in vitro fertilization-embryo transfer cycles. Fertil Steril 1999; 71: 294-301
104. Egbase PE, Al Sharhan M, Grudzinskas JG. 'Early coasting' in patients with polycystic ovarian syndrome is consistent with good clinical outcome. Hum Reprod 2002; 17: 1212-6
105. Al-Shawaf T, Zosmer A, Tozer A, et al. Value of measuring serum FSH in addition to serum estradiol in a coasting programme to prevent severe OHSS. Hum Reprod 2002; 17: 1217-121
106. Salat-Baroux J, Alvvarez S, Antoine JM, et al. Treatment of hyperstimulation during in-vitro fertilisation. Hum Reprod 1990; 5: 36-9
107. Forman RG, Frydman R, Egan D, et al. Severe ovarian hyperstimulation syndrome using agonists of gonadotropin-releasing hormone for in vitro fertilization: a European series and a proposal for prevention. Fertil Steril 1999; 53: 502-9
108. Imoedemhe DA, Sigue AB, Pacpaco EL, et al. Stimulation of endogenous surge of lutinizing hormone with gonadotrophin-releasing hormone analog after ovarian stimulation for in vitro fertilization. Fertil Steril 1991; 55: 328-32
109. Lewit N, Kol S, Manor D, et al. Comparison of gonadotrophin-releasing hormon analogues and human chorionic gonadotrophin for the introduction of ovulation andprevention of ovarian hyperstimulation syndrome: a case-control study. Hum Reprod 1996; 11: 1399-402
110. Amso NN, Ahuja KK, Moris N, et al. The management of predicted ovarian hyperstimulation involving gonadotrophin-releasing hormone analogue with elective cryopreservation of all pre-embryos. Fertil Steril 1990; 53: 1087-90
111. Queenan JT Jr, Veek LL, Toner JP, et al. Cryopreservation of all prezygotes in patients at risk of severe hyperstimulation does not eliminate the syndrome, but the chances of pregnency are excellent with subsequent frozen-thaw transfers. Hum Reprod 1997; 12: 1573-6
112. Wiener-Megnazi Z, Lahav-Baratz S, Rothschild E, et al. Impact of cryopreservation and subsequent embryo transfer on the outcome of in vitro fertilization in patients at high risk for ovarian hyperstimulation syndrome. Fertil Steril 2002; 7 8 (1): 201-3
113. D'Angelo A, Amso NN. Embryo freezing for preventing ovarian hyperstimulation syndrome: a Cochrane review. Hum Reprod 2002; 17 (11): 2787-94
114. Kinget H, Nijs M, Cox AM, et al. A novel approach for patients at risk for ovarian hyperstimulation syndrome: elective transfer of a single zona-free blastocyst on day 5. Reprod Biomed Online. 2002 Jan-Feb; 4 (1): 51-5
115. Asch RH, Ivery G, Goldsman M, et al. The use of intravenous albumin in patients at high risk for severe ovarian hyperstimulation syndrome. Hum Reprod 1993; 8: 1015-20
116. Shoham Z, Weissman A, Barash A, et al. Intravenous album for the prevention of severe ovarian hyperstimulation syndrome in an in vitro fertilization program: a prospective, randomized, placebo-controlled study. Fertil Steril 1994; 62: 137-42
117. Mukherjee T, Copperman AB, Sandler B, et al. Severe ovarian hyperstimulation syndrome despite prophylactic albumin at the time of oocyte retrieval for in vitro fertilisation and embryo transfer. Fertil Steril 1995; 64: 641-3
118. Ng E, Leader A, Claman P, et al. Intravenous albumin does not prevent the development of severe ovarian hyperstimulation syndrome in an in-vitro fertilization programme. Hum Reprod 1995; 10: 807-10
119. Ndukwe G, Thornton S, Fishel S, et al. Severe ovarian hyperstimulation syndrome: is it really preventable by prophylactic intravenous albumin? Fertil Steril 1997; 68: 851-4
120. Ben-Chetrit A, Eldar-Geva T, Gal M, et al. The questionable use of albumin for the prevention of ovarian hyperstimulation syndrome in an IVF programme: a randomized placebo-controlled trial. Hum Reprod 2001; 16 (9): 1880-4
121. Aboulghar M, Evers JH, Al-Inany H. Intra-venous albumin for preventing severe ovarian hyperstimulation syndrome. Cochran Database Syst Rev 2002; 2: CD001302
122. Lewit N, Kol S, Ronen N, et al. Does intravenous albumin administration of human albumin prevent severe ovarian hyperstimulation syndrome? Fertil steril 1996; 66: 654-56
123. Brinsden P, Wada I, Tan S, et al. Diagnosis, prevention and management of ovarian hyperstimulation syndrome. Br J Obstet Gynaecol 1995; 102: 767-72
124. Borenstein R, Elhalal U, Lunenfeld B, et al. Severe ovarian hyperstimulation syndrome: a re-evaluated therapeutic approach. Fertil Steril 1989; 51: 791-5
125. Abramov Y, Fatum M, Abrahamov D, et al. Hydroxyethyl starch versus human albumin for the treatment of severe ovarian hyperstimulation syndrome: a preliminary report. Fertil Steril 2001; 75: 18-30
126. Aboulghar MA, Mansour RT, Serour GI, et al. Management of severe ovarian hyperstimulation syndrome by ascitic fluid aspiration and intensive intravenous fluid therapy. Obstet Gynecol 1993; 81: 108-11
127. Delbaere A, Bergmann PJM, Gervy-Decoster C, et al. Angiotensin 2 immunoreactivitivity is elevated in ascites during severe ovarian hyperstimulation syndrome: implications for pathophysiology and clinical management. Fertil Steril 1994; 62: 731-7
128. Fluker MR, Copeland YE, Yuzpe AA. An ounce of prevention: outpatient management of the ovarian hyperstimulation syndrome. Fertil Steril 2000; 73: 821-4
129. Al-Shawaf T, Grudzinskas JG. Prevention and treatment of ovarian hyperstimulation syndrome. Best Pract Res Clin Obstet Gynaecol 2003; 17 (2): 249-61
130. Iwabe T, Harada T, Miura H, et al. Laparoscopic unwinding of adnexal torsion caused by ovarian hyperstimulation. Hum Reprod 1994; 9: 2350-2
131. Gnoth C, Halbe E, Freundl G. Persistent ascites after ovarian hyperstimulation syndrome and administration of mifepristone (RU 486) for the termination of pregnancy. Arch Gynecol Obstet 2003; 268 (1): 65-8
132. Bonduelle M, Liebaers I, Deketelaere V, et al. Neonatal data on a cohort of 2889 infants born after ICSI (1991-1999) and of 2995 infants born after IVF (1983-1999). Hum Reprod 2002; 17 (3): 671-94
133. Sutcliffe AG, Saunders K, McLachlan R, et al. A retrospective case-control study of developmental and other outcomes in a cohort of Australian children conceived by intracytoplasmic sperm injection compared with a similar group in the United Kingdom. Fertil Steril 2003; 79 (3): 512-6
134. Wennerholm UB, Bergh C. Obstetric outcome and follow-up of children born after in vitro fertilization (IVF). Hum Fertil (Camb) 2000; 3 (1): 52-64
135. Wennerholm UB, Bergh C, Hamberger L, et al. Incidence of congenital malformations in children born after ICSI. Hum Reprod 2000; 15 (4): 944-8
136. Hansen M, Kurinczuk JJ, Bower C, et al. The risk of major birth defects after intracytoplasmic sperm injection and in vitro fertilization. N Engl J Med 2002; 346 (10): 725-30
137. Shoham Z, Zosmer A, Insler V. Early miscarriage and fetal malformations after induction of ovulation (by clomiphene citrate and/or human menotropins), in vitro fertilization, and gamete intrafallopian transfer. Fertil Steril 1991; 55 (1): 1-11
138. Lass A, Croucher C, Duffy S, et al. One thousand initiated cycles of in vitro fertilisation in women > or = 40 years of age. Fertil Steril 1998; 70: 1030-4
139. Milsom SR, Gibson G, Buckingham K, et al. Factors associated with pregnancy or miscarriage after clomiphene therapy in WHO group II anovulatory women. Aust N Z J Obstet Gynaecol 2002; 42 (2): 170-5
140. Ranson MX, Bohrer M, Blotner MB, et al. The difference in miscarriage rates between menotropin induced and natural cycle pregnancies is not surveillance related. Fertil Steril 1993; 59: 567-70
141. Gianaroli L, Magli MC, Ferraretti AP, et al. Pre-implantation diagnosis for aneuploidies in patients undergoing in-vitro fertilisation with poor prognosis: identification of the categories to which it should be proposed. Fertil Steril 1999; 72: 837-44
142. Munne S, Cohen J, Sable D. Pre-implantation genetic diagnosis for advanced maternal age and other indications. Fertil Steril 2002; 78: 234-6
143. Wilton L, Voullaire L, Sargeant P, et al. Preimplantation aneuploidy screening using comparative genomic hybridization or fluorescence in situ hybridization of embryos from patients with recurrent implantation failure. Fertil Steril 2003; 80 (4): 860-8
144. Tanaka A, Nagayoshi M, Awata S, et al. Preimplantation diagnosis of repeated miscarriage due to chromosomal translocation susing metaphase chromosomes of a blastomere biopsied from 4- to 6-cell-stage embryos. Fertil Steril 2004; 81 (1): 30-4
145. CDC. Department of Human Health and Services, Centers for Disease Control and Prevention: 2002 assisted reproductive technology success rate [online]. Available from URL://www.cdc.gov/reproductivehealth/ARTQ/index.htm [Accessed 2005 May 4]
146. National data statistics: national figures for IVF and DI treatment (1999-2000 and 2000-2001) [online]. Available from URL: http://www.hfea.gov.uk {Accessed 2005 May 4]
147. Anderson A, Gianaroli L, Nygren KS. European IVF-monitoring programme: European Society of Human Reproduction and Embryology. Hum Reprod 2004; 19: 490-503
148. Templeton A, Morris JK. Reducing the risk of multiple births by transfer of two embryos after in-vitro fertilisation. N Engl J Med 1998; 339: 573-7
149. Marek D, Langley M, Gardner DK, et al. Introduction of blastocyst culture and transfer for all patients in an in-vitro fertilisation program. Fertil Steril 1999; 72: 1035-40
150. Svendsen TO, Jones D, Butler L, et al. The incidence of multiple gestations after in-vitro fertilisation is dependent on the number of embryos transferred and maternal age. Fertil Steril 1996; 65: 561-5
151. Callahan TL, Hall JE, Ettner SL, et al. The economic impact of multiple-gestation pregnancies and the contribution of assisted-reproduction techniques to their incidence. N Engl J Med 1994; 331: 244-9
152. Collins JA. Reproductive technology - the price of progress. N Engl J Med 1994; 331: 270-1